LON:AGY - Allergy Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 14.25 0.00 (0.00 %)
(As of 12/14/2018 04:00 PM ET)
Previous CloseGBX 14.25
Today's RangeGBX 14.10 - GBX 14.10
52-Week RangeGBX 23 - GBX 39.50
Volume2,000 shs
Average Volume167,682 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen. The company also provides Acarovac Plus, a novel microcrystalline tyrosine adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). In addition, it develops products based on synbiotics that are Kallergen Th and SynGut; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; Polyvac, a peanut vaccine; and G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolLON:AGY
Previous Symbol
CUSIPN/A
Phone+44-1903-844700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees499
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

What price target have analysts set for AGY?

1 analysts have issued 12-month price objectives for Allergy Therapeutics' stock. Their predictions range from GBX 45 to GBX 47. On average, they anticipate Allergy Therapeutics' share price to reach GBX 46 in the next twelve months. This suggests a possible upside of 222.8% from the stock's current price. View Analyst Price Targets for Allergy Therapeutics.

What is the consensus analysts' recommendation for Allergy Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergy Therapeutics.

Has Allergy Therapeutics been receiving favorable news coverage?

News articles about AGY stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergy Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next several days.

Who are some of Allergy Therapeutics' key competitors?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 54)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 53)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 14.25.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (LON AGY)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel